179385bb
2021-08-09
Like
BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech股价因盈利大幅增长而上涨;公司的目光超越了新冠疫情</blockquote>
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
2
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":898401853,"tweetId":"898401853","gmtCreate":1628515668472,"gmtModify":1631892500404,"author":{"id":4087793498322120,"idStr":"4087793498322120","authorId":4087793498322120,"authorIdStr":"4087793498322120","name":"179385bb","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/898401853","repostId":2158238441,"repostType":4,"repost":{"id":"2158238441","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1628514928,"share":"https://www.laohu8.com/m/news/2158238441?lang=zh_CN&edition=full","pubTime":"2021-08-09 21:15","market":"us","language":"en","title":"BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech股价因盈利大幅增长而上涨;公司的目光超越了新冠疫情</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2158238441","media":"Investors","summary":"BioNTech stock popped on Monday after reporting adjusted profit of $12.67 a share on $6.24 billion in second-quarter sales.","content":"<p>BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.</p><p><blockquote>BioNTech股价周一上涨,此前这家新冠疫苗制造商公布第二季度销售额为62.4亿美元,调整后每股利润为12.67美元。</blockquote></p><p> Analysts polled by FactSet expected <b>BioNTech</b> to earn $8.87 per share on $3.83 billion in sales.</p><p><blockquote>FactSet调查的分析师预期<b>BioNTech</b>销售额为38.3亿美元,每股收益为8.87美元。</blockquote></p><p> In the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.</p><p><blockquote>去年同期,BioNTech每股亏损45美分,营收为4900万美元。</blockquote></p><p> BioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the <b>Pfizer</b> partner to earn $33.12 a share on $14.68 billion in sales.</p><p><blockquote>BioNTech没有提供全年销售和盈利指引。该公司指出,它已达成协议,将在2021年提供22亿剂新冠疫苗,目前正在研究多种癌症药物。分析师呼吁<b>辉瑞</b>合作伙伴的销售额为146.8亿美元,每股收益为33.12美元。</blockquote></p><p> In premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.</p><p><blockquote>在今天股市的盘前交易中,BioNTech股价上涨5%,接近408.50点。根据IBD Digital的数据,该股的完美相对强度评级为99。就12个月的业绩而言,这使得BioNTech股票在所有公司中排名前1%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech股价因盈利大幅增长而上涨;公司的目光超越了新冠疫情</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech股价因盈利大幅增长而上涨;公司的目光超越了新冠疫情</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time smaller\">2021-08-09 21:15</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.</p><p><blockquote>BioNTech股价周一上涨,此前这家新冠疫苗制造商公布第二季度销售额为62.4亿美元,调整后每股利润为12.67美元。</blockquote></p><p> Analysts polled by FactSet expected <b>BioNTech</b> to earn $8.87 per share on $3.83 billion in sales.</p><p><blockquote>FactSet调查的分析师预期<b>BioNTech</b>销售额为38.3亿美元,每股收益为8.87美元。</blockquote></p><p> In the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.</p><p><blockquote>去年同期,BioNTech每股亏损45美分,营收为4900万美元。</blockquote></p><p> BioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the <b>Pfizer</b> partner to earn $33.12 a share on $14.68 billion in sales.</p><p><blockquote>BioNTech没有提供全年销售和盈利指引。该公司指出,它已达成协议,将在2021年提供22亿剂新冠疫苗,目前正在研究多种癌症药物。分析师呼吁<b>辉瑞</b>合作伙伴的销售额为146.8亿美元,每股收益为33.12美元。</blockquote></p><p> In premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.</p><p><blockquote>在今天股市的盘前交易中,BioNTech股价上涨5%,接近408.50点。根据IBD Digital的数据,该股的完美相对强度评级为99。就12个月的业绩而言,这使得BioNTech股票在所有公司中排名前1%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158238441","content_text":"BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.\nAnalysts polled by FactSet expected BioNTech to earn $8.87 per share on $3.83 billion in sales.\nIn the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.\nBioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the Pfizer partner to earn $33.12 a share on $14.68 billion in sales.\nIn premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.","news_type":1,"symbols_score_info":{"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":419,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/898401853"}
精彩评论